Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Infectious Disease Research Institute and Immune Design, a vaccine biotech company, have entered into an agreement pursuant to which Immune Design is granted a worldwide exclusive license for the research, development and commercialization of IDRI's glycopyranosyl lipid adjuvant technology for products targeting a number of indications.
Subscribe to our email newsletter
The Infectious Disease Research Institute (IDRI) retains worldwide exclusive rights to glycopyranosyl lipid adjuvant (GLA) for selected diseases affecting predominately the developing world. Under the agreement, IDRI will receive an upfront payment, milestones and royalty payments as well as shares in Immune Design. Further details on the financial terms were not disclosed.
As part of its commitment to provide the not-for-profit sector access to its adjuvant technology, IDRI also retains rights to conduct non-commercial research with GLA and will still have the right to provide it to not-for- profit organizations. Importantly, Immune Design has adopted a global access plan which addresses accessibility of GLA-containing products the company would develop for diseases of the developing world.
Curt Malloy, senior vice president of operations and general counsel at IDRI, said: “We are using GLA in several of IDRI’s priority programs but we also think that it has great potential against diseases outside our scope of action. While we retain the necessary rights to pursue our mission against diseases of poverty, revenues generated by this agreement will assist our R&D activities.”